Exact Mass: 303.1293

Exact Mass Matches: 303.1293

Found 92 metabolites which its exact mass value is equals to given mass value 303.1293, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Evodiamine

(1S)-21-METHYL-3,13,21-TRIAZAPENTACYCLO[11.8.0.0(2),(1)?.0?,?.0(1)?,(2)?]HENICOSA-2(10),4,6,8,15,17,19-HEPTAEN-14-ONE

C19H17N3O (303.1372)


Evodiamine is a member of beta-carbolines. Evodiamine is a natural product found in Vepris soyauxii, Cryptocarya, and other organisms with data available. Origin: Plant; Formula(Parent): C19H17N3O; Bottle Name:Evodiamine; PRIME Parent Name:Evodiamine; PRIME in-house No.:V0296; SubCategory_DNP: Monoterpenoid indole alkaloids, Indoloquinolizidine alkaloids, Indole alkaloids Formula(Parent): C19H17N3O; Bottle Name:Evodiamine; Origin: Plant; PRIME Parent Name:Evodiamine; PRIME in-house No.:V0296; SubCategory_DNP: Monoterpenoid indole alkaloids, Indoloquinolizidine alkaloids, Indole alkaloids Annotation level-1 (±)-Evodiamine, a quinazolinocarboline alkaloid, is a Top1 inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their apoptosis[1]. Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor. Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor.

   

Phenoxybenzamine

Wellspring brand OF phenoxybenzamine hydrochloride

C18H22ClNO (303.139)


Phenoxybenzamine is only found in individuals that have used or taken this drug. It is an alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator. [PubChem]Phenoxybenzamine produces its therapeutic actions by blocking alpha receptors, leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

Retigabine

Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride

C16H18FN3O2 (303.1383)


C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics D049990 - Membrane Transport Modulators Same as: D09569

   

Chlorphenoxamine

Chlorphenoxamine

C18H22ClNO (303.139)


D - Dermatologicals > D04 - Antipruritics, incl. antihistamines, anesthetics, etc. > D04A - Antipruritics, incl. antihistamines, anesthetics, etc. > D04AA - Antihistamines for topical use R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Chlorphenoxamine is an antihistamine and anticholinergic used as an antipruritic and antiparkinsonian agent. Target: Histamine Receptor

   

Pipemidic acid

5,8-Dihydro-8-ethyl-5-oxo-2-(1-piperazinyl)pyrido(2,3-D)pyrimidine-6-carboxylic acid

C14H17N5O3 (303.1331)


Pipemidic acid is a member of the pyridopyrimidine class of antibacterials, which display some overlap in mechanism of action with analogous pyridone-containing quinolones. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic C254 - Anti-Infective Agent > C255 - Urinary Anti-Infective Agent D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   

Indoleacetyl glutamine

4-carbamoyl-2-[2-(1H-indol-3-yl)acetamido]butanoic acid

C15H17N3O4 (303.1219)


Indoleacetyl glutamine is indolic derivative of tryptophan. It is generated from indoleacetic acid. Indoleacetic acid (IAA) is a breakdown product of tryptophan metabolism and is often produced by the action of bacteria in the mammalian gut. Some endogenous production of IAA in mammalian tissues also occurs. It may be produced by the decarboxylation of tryptamine or the oxidative deamination of tryptophan. Indoleacetyl glutamine frequently occurs at low levels in urine and has been found in elevated levels in the urine of patients with hartnup disease, the characteristic symptoms of the disease are mental retardation and pellagra like skin rash. [HMDB] Indoleacetyl glutamine is indolic derivative of tryptophan. It is generated from indoleacetic acid. Indoleacetic acid (IAA) is a breakdown product of tryptophan metabolism and is often produced by the action of bacteria in the mammalian gut. Some endogenous production of IAA in mammalian tissues also occurs. It may be produced by the decarboxylation of tryptamine or the oxidative deamination of tryptophan. Indoleacetyl glutamine frequently occurs at low levels in urine and has been found in elevated levels in the urine of patients with hartnup disease, the characteristic symptoms of the disease are mental retardation and pellagra like skin rash.

   

Chlorphenoxamine

{2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl}dimethylamine

C18H22ClNO (303.139)


D - Dermatologicals > D04 - Antipruritics, incl. antihistamines, anesthetics, etc. > D04A - Antipruritics, incl. antihistamines, anesthetics, etc. > D04AA - Antihistamines for topical use R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Chlorphenoxamine is a first-generation ethanolamine H1-antihistamine. Chlorphenoxamine is an antihistamine and anticholinergic used as an antipruritic and antiparkinsonian agent. Target: Histamine Receptor

   

(2E)-4-Hydroxy-3-methylpent-2-enedioylcarnitine

3-[(4-carboxy-2-hydroxy-3-methylbut-3-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C13H21NO7 (303.1318)


(2E)-4-hydroxy-3-methylpent-2-enedioylcarnitine is an acylcarnitine. More specifically, it is an (2E)-4-hydroxy-3-methylpent-2-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-4-hydroxy-3-methylpent-2-enedioylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine (2E)-4-hydroxy-3-methylpent-2-enedioylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular (2E)-4-hydroxy-3-methylpent-2-enedioylcarnitine is elevated in the blood or plasma of individuals with 3-hydroxy-3-ethylglutarylCoA lyase deficiency (PMID: 32685354). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(1-(3-Isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate

(1-(3-Isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulphonic acid

C12H21N3O4S (303.1253)


   

5-Pyrimidinecarboxylic acid, 1,4-dihydro-2-((2-(2-methylpropoxy)phenyl)amino)-4-oxo-

5-Pyrimidinecarboxylic acid, 1,4-dihydro-2-((2-(2-methylpropoxy)phenyl)amino)-4-oxo-

C15H17N3O4 (303.1219)


   

3-(2-Chlorophenyl)-N-(1-(3-methoxyphenyl)ethyl)propan-1-amine

3-(2-Chlorophenyl)-N-(1-(3-methoxyphenyl)ethyl)propan-1-amine

C18H22ClNO (303.139)


   

Evodiamine

21-methyl-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15,17,19-heptaen-14-one

C19H17N3O (303.1372)


(±)-Evodiamine, a quinazolinocarboline alkaloid, is a Top1 inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their apoptosis[1].

   
   
   

Mycosporine glutamicol

Mycosporine glutamicol

C13H21NO7 (303.1318)


   

Methyl 2,3-di-O-acetyl-4-(acetylamino)-4,6-dideoxyhexopyranoside #

Methyl 2,3-di-O-acetyl-4-(acetylamino)-4,6-dideoxyhexopyranoside #

C13H21NO7 (303.1318)


   
   

Me glycoside,N-Ac,2,4-di-O Ac-beta-D-Pyranose-3-Amino-3,6-dideoxygalactose

Me glycoside,N-Ac,2,4-di-O Ac-beta-D-Pyranose-3-Amino-3,6-dideoxygalactose

C13H21NO7 (303.1318)


   

(13bS)-8,13,13b,14-tetrahydro-1-methylindolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridin-5(7H)-one|Latifoliamide D

(13bS)-8,13,13b,14-tetrahydro-1-methylindolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridin-5(7H)-one|Latifoliamide D

C19H17N3O (303.1372)


   
   
   
   
   

(±)-Evodiamine

(+/-)-Evodiamine

C19H17N3O (303.1372)


(±)-Evodiamine, a quinazolinocarboline alkaloid, is a Top1 inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their apoptosis[1].

   
   

Pipemidic acid

Pipemidic acid

C14H17N5O3 (303.1331)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic C254 - Anti-Infective Agent > C255 - Urinary Anti-Infective Agent D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3075

   

phenoxybenzamine

phenoxybenzamine

C18H22ClNO (303.139)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents KEIO_ID P206; [MS2] KO009176 KEIO_ID P206

   
   
   
   
   
   
   
   

Acarbose (component 1)

Acarbose (component 1)

C13H21NO7 (303.1318)


   

ethyltris(2-hydroxyethyl)ammonium ethyl sulphate

ethyltris(2-hydroxyethyl)ammonium ethyl sulphate

C10H25NO7S (303.1352)


   

2-Acetamido-2-deoxy-4,6-O-isopropylidene-D-glucopyranose

2-Acetamido-2-deoxy-4,6-O-isopropylidene-D-glucopyranose

C13H21NO7 (303.1318)


   

2-Methoxy-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester

2-Methoxy-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester

C13H17BF3NO3 (303.1254)


   

Uracil,6-amino-5-(2-anilinoacetamido)-1,3-dimethyl- (5CI)

Uracil,6-amino-5-(2-anilinoacetamido)-1,3-dimethyl- (5CI)

C14H17N5O3 (303.1331)


   

4-tert-butyl-N-(4-methylphenyl)benzenesulfonamide

4-tert-butyl-N-(4-methylphenyl)benzenesulfonamide

C17H21NO2S (303.1293)


   

Benzyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate

Benzyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate

C15H17N3O4 (303.1219)


   

Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(4-fluorophenyl)-1-piperazinyl]

Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(4-fluorophenyl)-1-piperazinyl]

C16H18FN3O2 (303.1383)


   

Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(2-fluorophenyl)-1-piperazinyl]-

Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(2-fluorophenyl)-1-piperazinyl]-

C16H18FN3O2 (303.1383)


   

Ethyl 1-[4-(trifluoromethyl)pyrimidin-2-yl]piperidine-4-carboxylate

Ethyl 1-[4-(trifluoromethyl)pyrimidin-2-yl]piperidine-4-carboxylate

C13H16F3N3O2 (303.1195)


   

1H-Indole-1-carboxylic acid, 5-acetyl-2-borono-, 1-(1,1-dimethylethyl) ester (9CI)

1H-Indole-1-carboxylic acid, 5-acetyl-2-borono-, 1-(1,1-dimethylethyl) ester (9CI)

C15H18BNO5 (303.1278)


   

Metadin

Pipradrol hydrochloride

C18H22ClNO (303.139)


   

Pipemidic acid trihydrate

Pipemidic acid trihydrate

C14H17N5O3 (303.1331)


   

5,6-Dihydro-3-(4-morpholinyl)-1-(4-nitrophenyl)-2(1H)-pyridinone

5,6-Dihydro-3-(4-morpholinyl)-1-(4-nitrophenyl)-2(1H)-pyridinone

C15H17N3O4 (303.1219)


   

1H-pyrazolo[3,4-b]pyridine-5-carbonitrile

1H-pyrazolo[3,4-b]pyridine-5-carbonitrile

C15H17N3O4 (303.1219)


   

2-[5-[morpholin-4-yl(phenyl)methyl]tetrazol-1-yl]acetic acid

2-[5-[morpholin-4-yl(phenyl)methyl]tetrazol-1-yl]acetic acid

C14H17N5O3 (303.1331)


   

4-(dicyanomethylene)-2-methyl-6-(4-(dimethylamino)styryl)-4H-pyran

4-(dicyanomethylene)-2-methyl-6-(4-(dimethylamino)styryl)-4H-pyran

C19H17N3O (303.1372)


   

ETHYL 2-(2-[4-(TERT-BUTYL)PHENYL]-1,3-THIAZOL-4-YL)ACETATE

ETHYL 2-(2-[4-(TERT-BUTYL)PHENYL]-1,3-THIAZOL-4-YL)ACETATE

C17H21NO2S (303.1293)


   

2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethoxy)aniline

2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethoxy)aniline

C13H17BF3NO3 (303.1254)


   

1-Methyl-4-(4-nitro-2-(trifluoromethyl)benzyl)piperazine

1-Methyl-4-(4-nitro-2-(trifluoromethyl)benzyl)piperazine

C13H16F3N3O2 (303.1195)


   

Diphenylpiperidin-4-ylmethanol hydrochloride

Diphenylpiperidin-4-ylmethanol hydrochloride

C18H22ClNO (303.139)


   

4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethoxy)aniline

4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethoxy)aniline

C13H17BF3NO3 (303.1254)


   

2,5-Diethoxy-4-((4-methylphenyl)thio)aniline

2,5-Diethoxy-4-((4-methylphenyl)thio)aniline

C17H21NO2S (303.1293)


   

2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)pyridine

2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)pyridine

C13H17BF3NO3 (303.1254)


   

1-(3-Chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropanecarbonitrile

1-(3-Chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropanecarbonitrile

C16H19BClNO2 (303.1197)


   

5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRIMIDIN-2-AMINE

5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRIMIDIN-2-AMINE

C12H17BF3N3O2 (303.1366)


   

N,N-Diphenyl-4-methoxybenzamide

N,N-Diphenyl-4-methoxybenzamide

C20H17NO2 (303.1259)


   

2-(2,2,2-Trifluoroethoxy)pyridine-3-boronic acid pinacol ester

2-(2,2,2-Trifluoroethoxy)pyridine-3-boronic acid pinacol ester

C13H17BF3NO3 (303.1254)


   

4-Diphenylmethoxypiperidine hydrochloride

4-Diphenylmethoxypiperidine hydrochloride

C18H22ClNO (303.139)


   

N-(indol-3-ylacetyl)glutamine

N-(indol-3-ylacetyl)glutamine

C15H17N3O4 (303.1219)


A N(2)-acylglutamine that has indol-3-ylacetyl as the acyl group.

   
   

3-(4-Phenylamino-phenylamino)-2-(1H-tetrazol-5-YL)-acrylonitrile

3-(4-Phenylamino-phenylamino)-2-(1H-tetrazol-5-YL)-acrylonitrile

C16H13N7 (303.1232)


   

Retigabine

Retigabine

C16H18FN3O2 (303.1383)


C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics D049990 - Membrane Transport Modulators

   

D-nopalinate(1-)

D-nopalinate(1-)

C11H19N4O6- (303.1305)


Conjugate base of D-nopaline in which the three carboxy groups are anionic and the secondary amino and guanidino groups are cationic; major species at pH 7.3.

   

Indol-3-ylacetylglutamine

Indol-3-ylacetylglutamine

C15H17N3O4 (303.1219)


   

(2E)-4-Hydroxy-3-methylpent-2-enedioylcarnitine

(2E)-4-Hydroxy-3-methylpent-2-enedioylcarnitine

C13H21NO7 (303.1318)


   

N-hydroxy-7-(naphthalen-2-ylthio)heptanamide

N-hydroxy-7-(naphthalen-2-ylthio)heptanamide

C17H21NO2S (303.1293)


D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors

   

7-methyl-7,8-dihydro-6H-dichromeno[3,2-c:2,3-d]pyridine

7-methyl-7,8-dihydro-6H-dichromeno[3,2-c:2,3-d]pyridine

C20H17NO2 (303.1259)


   

1-[[(1-Methyl-2-benzimidazolyl)amino]methyl]-2-naphthalenol

1-[[(1-Methyl-2-benzimidazolyl)amino]methyl]-2-naphthalenol

C19H17N3O (303.1372)


   

1-(1-Adamantyl)-2-[(1-oxido-2-pyridin-1-iumyl)thio]ethanone

1-(1-Adamantyl)-2-[(1-oxido-2-pyridin-1-iumyl)thio]ethanone

C17H21NO2S (303.1293)


   

Indolacetylglutamin

Indolacetylglutamin

C15H17N3O4 (303.1219)


   

4,6-Dimethyl-3-(3-naphthalen-1-yl-acryloyl)-1H-pyridin-2-one

4,6-Dimethyl-3-(3-naphthalen-1-yl-acryloyl)-1H-pyridin-2-one

C20H17NO2 (303.1259)


   

5-[(3-Hydroxypropylamino)methylidene]-1-(phenylmethyl)-1,3-diazinane-2,4,6-trione

5-[(3-Hydroxypropylamino)methylidene]-1-(phenylmethyl)-1,3-diazinane-2,4,6-trione

C15H17N3O4 (303.1219)


   

N-[(3,5-dimethoxyphenyl)methyl]-1-[4-(methylthio)phenyl]methanamine

N-[(3,5-dimethoxyphenyl)methyl]-1-[4-(methylthio)phenyl]methanamine

C17H21NO2S (303.1293)


   
   

6,8,10-Trimethylbenzo[4,5]cyclohepta[1,2-b]indole-9,11-diol

6,8,10-Trimethylbenzo[4,5]cyclohepta[1,2-b]indole-9,11-diol

C20H17NO2 (303.1259)


   

N-[(Z)-1H-indol-3-ylmethylideneamino]-2-phenylcyclopropane-1-carboxamide

N-[(Z)-1H-indol-3-ylmethylideneamino]-2-phenylcyclopropane-1-carboxamide

C19H17N3O (303.1372)


   
   
   
   
   

D-23129

N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester

C16H18FN3O2 (303.1383)


C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics D049990 - Membrane Transport Modulators Same as: D09569

   

2-methyl-10-{[(1e)-2-phenylethenyl]amino}-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1(12),3,7,9-tetraen-11-one

2-methyl-10-{[(1e)-2-phenylethenyl]amino}-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1(12),3,7,9-tetraen-11-one

C19H17N3O (303.1372)


   

(1r)-21-methyl-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15,17,19-heptaen-14-one

(1r)-21-methyl-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15,17,19-heptaen-14-one

C19H17N3O (303.1372)


   

5-hydroxy-4-{[5-hydroxy-5-(hydroxymethyl)-2-methoxy-3-oxocyclohex-1-en-1-yl]amino}pentanoic acid

5-hydroxy-4-{[5-hydroxy-5-(hydroxymethyl)-2-methoxy-3-oxocyclohex-1-en-1-yl]amino}pentanoic acid

C13H21NO7 (303.1318)


   

2-methyl-10-[(2-phenylethenyl)amino]-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1(12),3,7,9-tetraen-11-one

2-methyl-10-[(2-phenylethenyl)amino]-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1(12),3,7,9-tetraen-11-one

C19H17N3O (303.1372)


   

(4s)-5-hydroxy-4-{[(5s)-5-hydroxy-5-(hydroxymethyl)-2-methoxy-3-oxocyclohex-1-en-1-yl]amino}pentanoic acid

(4s)-5-hydroxy-4-{[(5s)-5-hydroxy-5-(hydroxymethyl)-2-methoxy-3-oxocyclohex-1-en-1-yl]amino}pentanoic acid

C13H21NO7 (303.1318)